vimarsana.com

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States ,Toronto ,Ontario ,Canada ,Krisv Kowdley ,Gideon Hirshfield ,Clin Gastroenterol Hepatol ,Christopher Keenan ,Terry Horner ,Drug Administration ,Youtube ,European Medicines Agency ,Clinical Development Next ,University Of Toronto ,Facebook ,Pliant Therapeutics Inc ,Linkedin ,Liver Institute ,Nasdaq ,Corporate Communications ,Enhanced Liver Fibrosis ,Chief Medical Officer ,Well Tolerated ,Serious Adverse ,Mayo Score ,Demonstrated Antifibrotic Activity ,Suspected Moderate ,Severe Liver Fibrosis ,Itch Numerical Rating Scale ,Liver Institute Northwest ,Washington State ,Development Next ,Primary Sclerosing ,Terry Horner Chair ,Autoimmune Liver Disease ,Pliant Therapeutics ,Fast Track Designation ,Orphan Drug Designation ,Private Securities Litigation Reform Act ,Financial Condition ,Quarterly Report ,Media Contact ,Investor Relations ,Magn Reson ,

vimarsana.com © 2020. All Rights Reserved.